Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Trending in China: Jack Ma Sells $8.2 Billion of Alibaba Shares — Good News for Philanthropy or Bad News for Tech Companies?
Didi to March Into 20 New Australian Cities Next Month
Underwater Robotics Maker Sublue Speeds Toward STAR Board Listing with New Funding
Suning.com Predicts Over $20 Million in Losses in First Half of 2020, Says Carrefour China Remains Profitable
Online Travel Leader Trip.com to Issue $500 Million in Convertible Bonds
Trending in China: Was the Driver Who Deliberately Crashed His Bus Killing 21 Evil or a Victim? Netizens Discuss
Foxconn Plans to Invest $1 Billion to Expand iPhone Production at Indian Factory: Reuters
Money-Losing Electric Carmaker Li Auto Files for U.S. IPO
Platform Serving China’s Takeout Delivery Workers Jumps 28% in Nasdaq Debut
SenseTime Builds AI Computing Platform in Shanghai Amid ‘New Infrastructure’ Push
WeRide to Test Fully Autonomous Vehicles in Guangzhou
Trending in China: Why Are Chinese Netizens Saying Kanye West Could be ‘China’s First’ U.S. President?
Trending in China: Will Weibo’s Fight Against Porn Have Other Unintended Side Effects
Tencent Leads $40 Million Investment in Online Art Educator
Alibaba Aims to Facilitate $1.4 Trillion in Sales Annually By 2024
Trending in China: Death of Giant Panda Cubs Sparks Concerns About Treatment of ‘National Treasure’
China CFO of Indian Oyo Quits to ‘Pursue Other Professional Opportunities’
Sequoia Capital Opens Its First Tech Incubation Center in Shanghai
Some 266 Foreign-Invested Firms Approved to Offer Telecom Services in China in First Half of 2020
Trending in China: Should Internet Celebrities Be Part of the School Curriculum?
Chinese Scientists Edit DNA in Attempt to Cure Man’s Cancer, HIV

By Bloomberg / Sep 12, 2019 11:16 AM / Business & Tech

Photo: VCG

Photo: VCG

Chinese researchers safely treated a man with leukemia and HIV using gene-edited stem cells, a step forward in a field that was shaken last year when another Chinese scientist used the same technology to create the world’s first genetically-edited babies.

The man’s medical case, published Wednesday in the New England Journal of Medicine, is the first detailed report in a major academic journal of how doctors are using the experimental tool Crispr to manipulate the DNA of a living patient in an effort to cure disease. But even before the earlier controversy in China, there’s been a heavy note of caution in the field about how far and fast to proceed with the technology.

The patient’s dual diseases — HIV and cancer — gave researchers at the Peking University Stem Cell Research Center in Beijing an opening. The man needed a transplant of stem cells to replace the damaged ones that were causing his blood cancer. That procedure also gave them the opportunity to re-engineer a gene called CCR5 in the donor cells to be resistant to HIV.

“This is a green light for the whole field of gene editing,” Carl June, a pioneer in the use of gene therapy to treat cancer and HIV at the University of Pennsylvania, said in an interview. He published a companion piece in the journal.

Related: Peking University Scientists Pioneer New Gene-Editing Technology

Share this article
Open WeChat and scan the QR code